open access
LCZ696 breakthrough in the treatment of chronic heart failure with reduced left ventricular ejection fraction
open access
Abstract
Heart failure is a common clinical problem; in developed countries it occurs in 1–2% of the adult population. Despite advances in treatment, outcome the prognosis in this disease remains unfavourable. In the pathophysiology of heart failure with reduced ejection fraction fundamental role play neurohormonal pathways, mainly the activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system, and natriuretic peptides. In the pharmacotherapy of heart failure promising are drugs that modulate the neurohormonal pathways. The paper presents the key results of clinical trials with the new molecule LCZ696, the first angiotensin receptor neprilysin inhibitor (ARNI).
Abstract
Heart failure is a common clinical problem; in developed countries it occurs in 1–2% of the adult population. Despite advances in treatment, outcome the prognosis in this disease remains unfavourable. In the pathophysiology of heart failure with reduced ejection fraction fundamental role play neurohormonal pathways, mainly the activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system, and natriuretic peptides. In the pharmacotherapy of heart failure promising are drugs that modulate the neurohormonal pathways. The paper presents the key results of clinical trials with the new molecule LCZ696, the first angiotensin receptor neprilysin inhibitor (ARNI).
Keywords
heart failure, neurohormonal system modulation, angiotensin receptor II blocker and neprilysin inhibitor, ARNI
About this articleTitle
LCZ696 breakthrough in the treatment of chronic heart failure with reduced left ventricular ejection fraction
Journal
Issue
Article type
Review paper
Pages
403-409
Published online
2016-01-11
DOI
10.5603/FC.2015.0077
Bibliographic record
Folia Cardiologica 2015;10(6):403-409.
Keywords
heart failure
neurohormonal system modulation
angiotensin receptor II blocker and neprilysin inhibitor
ARNI
Authors
Sebastian Sobczak
Małgorzata Lelonek